La utilidad de la nitroglicerina tópica al 0, 2% en la condrodermatitis nodular del hélix / The Usefulness of 0. 2% Topical Nitroglycerin for Chondrodermatitis Nodularis Helicis

INTRODUCCIÓN: La condrodermatitis nodular del hélix (CNH) es un proceso idiopático, degenerativo y doloroso que afecta a la piel y al cartílago del hélix o del antéhelix. Recientemente se ha descrito la utilidad de la nitroglicerina (NTG) tópica a 2% en el tratamiento de la CNH con buenos resultados, aunque con una tasa de efectos secundarios en el 17% de los casos. Es probable que a una concentración menor se pueda mantener el mismo efecto mejorando la tolerancia. Nuestra finalidad fue evaluar la efectividad y seguridad de la NTG tópica al 0,2% para el tratamiento de la CNH. MATERIAL Y MÉTODOS: Se llevó a cabo un estudio observacional retrospectivo entre los años 2012 y 2014 en 2 centros hospitalarios españoles. La efectividad se determinó a través de la evaluación clínica, realizada mediante seguimiento fotográfico, y de los síntomas de la lesión, medido mediante una escala numérica verbal. RESULTADOS: Veintinueve pacientes recibieron el tratamiento, de los cuales el 93% manifestaron una mejoría clínica con una duración media del tratamiento de 1,8 meses y un tiempo de seguimiento medio en los pacientes respondedores de 5,9 meses. La tolerancia fue buena en general en todos los casos. CONCLUSIÓN: La NTG tópica al 0,2% se plantea como una opción conservadora, efectiva y bien tolerada para el tratamiento de la condrodermatitis nodular del hélix que mejora tanto la apariencia clínica como la sintomatología en la mayoría de los pacientes

BACKGROUND AND OBJECTIVE: Chondrodermatitis nodularis helicis (CNH) is a painful idiopathic degenerative condition involving the skin and cartilage of the helix or antihelix of the ear. Topical nitroglycerin 2% is a relatively recent treatment option for CNH that has produced good results, although with adverse effects (17% of cases). The use of a lower concentration would probably achieve similar results with fewer adverse effects. The aim of this study was to evaluate the effectiveness and safety of topical nitroglycerin 0.2% in the treatment of CNH. MATERIAL AND METHODS: We performed a retrospective observational study of patients treated in 2 Spanish hospitals between 2012 and 2014. The effectiveness of treatment was determined by clinical photography and assessment of symptoms using a verbal numerical rating scale. RESULTS: Of the 29 patients treated, 93% showed clinical improvement. In the group of responders, mean treatment duration was 1.8 months and mean follow-up was 5.9 months. Overall tolerance was good in all cases. CONCLUSION: Topical nitroglycerin 0.2% is an effective and well-tolerated conservative treatment option that improves the appearance of lesions and provides symptomatic relief in the majority of patients with CNH

The Usefulness of 0.2% Topical Nitroglycerin for Chondrodermatitis Nodularis Helicis.

BACKGROUND AND OBJECTIVE: Chondrodermatitis nodularis helicis (CNH) is a painful idiopathic degenerative condition involving the skin and cartilage of the helix or antihelix of the ear. Topical nitroglycerin 2% is a relatively recent treatment option for CNH that has produced good results, although with adverse effects (17% of cases). The use of a lower concentration would probably achieve similar results with fewer adverse effects. The aim of this study was to evaluate the effectiveness and safety of topical nitroglycerin 0.2% in the treatment of CNH. MATERIAL AND METHODS: We performed a retrospective observational study of patients treated in 2 Spanish hospitals between 2012 and 2014. The effectiveness of treatment was determined by clinical photography and assessment of symptoms using a verbal numerical rating scale. RESULTS: Of the 29 patients treated, 93% showed clinical improvement. In the group of responders, mean treatment duration was 1.8 months and mean follow-up was 5.9 months. Overall tolerance was good in all cases. CONCLUSION: Topical nitroglycerin 0.2% is an effective and well-tolerated conservative treatment option that improves the appearance of lesions and provides symptomatic relief in the majority of patients with CNH.

Sarcoidosis cutánea. Opciones terapéuticas / Cutaneous sarcoidosis. Therapeutic choices

La Sarcoidosis es una enfermedad multisistémica que se caracteriza histológicamente por existencia de granulomas epiteliodes sin necrosis caseosa. Laafectación cutánea aparece en un 20-35% de los pacientes con sarcoidosis sistémica pero también puede aparecer como única manifestación de laenfermedad. Describimos un paciente afecto de sarcoidosis cutánea sin afectación sistémica. Las lesiones cutáneas no respondieron tras varios tratamientostópicos y sistémicos y finalmente respondieron a metotrexato. Revisamos las diferentes opciones en el tratamiento de la sarcoidosis cutánea (AU)

Sarcoidosis is a multisystemic disorder characterized histollogically by epithelioid granulomas without caseating necrosis. Cutaneous involvementoccurs in 20-35% of patients with systemic sarcoidosis and may occur without systemic involvement. A patient with cutaneous sarcoidosis, withoutsystemic involvement is reported. Cutaneous lesions do not responsive to various forms of topical and systemic treatment and finally were responsiveto metotrexate. We review treatment options for cutaneous sarcoidosis (AU)

[Adenoid cystic carcinoma]. / Carcinoma adenoide quístico.

Adenoid cystic carcinoma is an uncommon tumor of the head and neck. Although it is mainly located in the salivary gland, a skin location has also been described. Metastases are rare, but 50 % of the cases relapse. A 65-year-old male patient had a lesion in the upper lip. After resection, the histological diagnosis was adenoid cystic carcinoma. Treatment was completed with radiotherapy. Ten years later, a nodule was detected in the neck. Its histological diagnosis was lymphatic metastasis due to adenoid cystic carcinoma. Primary cutaneous adenoid cystic carcinoma is a very uncommon tumor in which treatment consists in extensive local excision with free margins. Radiotherapy is not curative and should be reserved for palliative treatments. Multicenter, prospective studies are necessary to determine the best treatment and especially the adjuvant treatment for adenoid cystic carcinoma.

Carcinoma adenoide quístico / Adenoid cystic carcinoma

El carcinoma adenoide quístico es un tumor poco común de cabeza y cuello, que si bien se localiza preferentemente en la glándula salivar, también se ha descrito su localización cutánea. Las metástasis son raras, pero un 50 % de los casos recidivan. Un paciente de 65 años de edad presentó una lesión en el labio superior, que tras la resección, el diagnóstico histopatológico fue de carcinoma adenoide quístico. El tratamiento se completó con radioterapia. Diez años más tarde se detectó un nódulo en el cuello cuyo diagnóstico histopatológico fue de metástasis linfática por carcinoma adenoide quístico. El carcinoma adenoide quístico, primariamente cutáneo, es un tumor muy poco frecuente en el que el tratamiento consiste en la exéresis local amplia con márgenes libres. La radioterapia no es curativa y debería reservarse para tratamientos paliativos. Se necesitan estudios multicéntricos prospectivos para determinar el tratamiento óptimo y, especialmente, el tratamiento adjuvante del carcinoma adenoide quístico

Adenoid cystic carcinoma is an uncommon tumor of the head and neck. Although it is mainly located in the salivary gland, a skin location has also been described. Metastases are rare, but 50 % of the cases relapse. A 65-year-old male patient had a lesion in the upper lip. After resection, the histological diagnosis was adenoid cystic carcinoma. Treatment was completed with radiotherapy. Ten years later, a nodule was detected in the neck. Its histological diagnosis was lymphatic metastasis due to adenoid cystic carcinoma. Primary cutaneous adenoid cystic carcinoma is a very uncommon tumor in which treatment consists in extensive local excision with free margins. Radiotherapy is not curative and should be reserved for palliative treatments. Multicenter, prospective studies are necessary to determine the best treatment and especially the adjuvant treatment for adenoid cystic carcinoma